| Institute for Research & Innovation |
Type II Diabetes - Mellitus & High Cardiovascular Risk
Study Number: 10-END-06Age: 18 yrs or older
Sex: Males and Females
Visits: Patients will have office visits for a maximum of 4 years (52 weeks treatment followed by 3 annual continuation visits for up to 3 years)
Stipend: You will be compensated for your time and travel
Principal Investigator(s): Ronald Graf, MD
Study Coordinator: Shannon Harris, Research Coordinator 253-301-6992
Purpose: To investigate the efficacy and safety of XXX treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.